A Prospective Study to Evaluate Alterations in Molecular Biomarkers in HER2 Neu Positive Metastatic Breast Cancer Together With Assessment of Trastuzumab Use Beyond Progression After Initial Response to Trastuzumab-taxane Based Treatment
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Time to progression
Event driven--monitored at each clinic visit
No
Clinical Trials
Study Director
Hoffmann-La Roche
Australia: National Health and Medical Research Council
MO22004
NCT00885755
August 2009
April 2014
Name | Location |
---|